
Please try another search
Investors focused on the Medical space have likely heard of Verastem (VSTM), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of VSTM and the rest of the Medical group's stocks.
Verastem is a member of our Medical group, which includes 898 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. VSTM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for VSTM's full-year earnings has moved 56.38% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, VSTM has returned 23.88% so far this year. Meanwhile, stocks in the Medical group have lost about 19.51% on average. As we can see, Verastem is performing better than its sector in the calendar year.
Breaking things down more, VSTM is a member of the Medical - Biomedical and Genetics industry, which includes 385 individual companies and currently sits at #73 in the Zacks Industry Rank. On average, this group has lost an average of 13.20% so far this year, meaning that VSTM is performing better in terms of year-to-date returns.
VSTM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
In a market fraught with uncertainty, investors often seek refuge in defensive-minded stocks that offer stability and resilience. Two such stalwarts, Johnson & Johnson and...
Bitcoin has gained legitimacy as it has achieved mainstream status these days. Even the United States Securities and Exchange Commission (SEC) has acknowledged its legitimacy with...
Stocks fell sharply, with the S&P 500 leading the decline, finishing the day down almost 1.6% at 5,860. Meanwhile, the Nasdaq 100 dropped nearly 2.75%, closing at 20,550. This...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.